News Quantified

GALT – galectin therapeutics inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update [Yahoo! Finance]

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. [Yahoo! Finance]

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

Form S-3 GALECTIN THERAPEUTICS

Form 8-K GALECTIN THERAPEUTICS For: Mar 31

Form 10-K GALECTIN THERAPEUTICS For: Dec 31

Form 4 GALECTIN THERAPEUTICS For: Mar 12 Filed by: Brem Henry

Form 3 GALECTIN THERAPEUTICS For: Mar 12 Filed by: Brem Henry

Top News Gainers

2/10 Form 4 GALECTIN THERAPEUTICS For: Feb 09 Filed by: LEWIS JOEL 11.8%

11/11 Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis 9.8%

8/9 Form S-3 GALECTIN THERAPEUTICS 7.8%

10/23 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. 6.7%

3/20 Form 4 GALECTIN THERAPEUTICS For: Mar 19 Filed by: FREEMAN KEVIN D 6.7%

2/20 Form 8-K GALECTIN THERAPEUTICS For: Feb 19 6.3%

3/16 Form 3 GALECTIN THERAPEUTICS For: Mar 02 Filed by: Boudes Pol F 4.8%

10/17 Form DEF 14A GALECTIN THERAPEUTICS For: Dec 04 3.6%

6/3 Form 4 GALECTIN THERAPEUTICS For: May 29 Filed by: Uihlein Richard E 3.6%

2/4 Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020 2.8%

Top News Decliners

3/16 Form 8-K GALECTIN THERAPEUTICS For: Mar 16 -17.0%

11/12 Form 10-Q GALECTIN THERAPEUTICS For: Sep 30 -16.9%

4/30 Form 8-K GALECTIN THERAPEUTICS For: Apr 30 -9.0%

4/2 Galectin Therapeutics Update on the Impact of COVID-19 -6.1%

10/24 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%

12/4 Form 8-K GALECTIN THERAPEUTICS For: Dec 04 -5.6%

8/13 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%

8/9 Q2/2019 6/30/2019 EPS -0.060 ZacksConsensus -0.120 ActVsEst 0.060 - Beat -4.8%

11/15 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -4.3%

7/25 Form 4 GALECTIN THERAPEUTICS For: Jul 15 Filed by: 10X Capital Management, LLC -4.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day